Ecto-5'-nucleotidase can provide the total purine requirements of mitogen-stimulated human T cells and rapidly dividing human B lymphoblastoid cells.
The ability of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells to drive their total purine requirements from inosine 5'-monophosphate, inosine, or hypoxanthine was compared. Inosine 5'-monophosphate first must be converted to inosine by the action of the enzyme ecto-5'-nucleotidase before it can be transported into the cell; inosine and hypoxanthine, however, can be transported directly. Mitogen-stimulated human peripheral blood T cells were treated with aminopterin to inhibit purine synthesis de novo and to make the cells dependent on an exogenous purine source. Thymidine was added as a source of pyrimidines. Under these conditions, 30 microM inosine 5'-monophosphate, inosine, and hypoxanthine showed comparable abilities to support [3H]thymidine incorporation into DNA or [3H]leucine incorporation into protein at rates equal to that of untreated control cultures. Similar results were found when azaserine was used to inhibit purine synthesis de novo, and thus DNA synthesis. In parallel experiments with the rapidly dividing human B lymphoblastoid cell line WI-L2, treatment with aminopterin (plus thymidine) inhibited the growth rate by greater than 95%. The normal growth rate was restored by the addition of 30 microM inosine 5'-monophosphate, inosine, or hypoxanthine to the medium. However, in similar experiments with cell line 1254, a derivative of WI-L2 which lacks detectable ecto-5'-nucleotidase activity, inosine and hypoxanthine (plus thymidine), but not inosine 5'-monophosphate (and thymidine) were able to restore the growth inhibition due to aminopterin. These results show that the catalytic activity of ecto-5'-nucleotidase is sufficient to meet the total purine requirements of mitogen-stimulated human T cells or rapidly dividing human B lymphoblastoid cells, and suggest that this enzyme may be important for purine salvage when rates of purine synthesis de novo are limited and/or an extracellular source of purine nucleotides is available.
Thompson
L F
LF
D015720:5'-Nucleotidase; D000630:Aminopterin / Q000494:pharmacology; D001377:Azaserine / Q000494:pharmacology; D001402:B-Lymphocytes / Q000201:enzymology*; D001798:Blood Proteins / Q000096:biosynthesis; D002460:Cell Line; D004247:DNA / Q000096:biosynthesis; D004355:Drug Stability; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000494:pharmacology; D007288:Inosine / Q000494:pharmacology; D007291:Inosine Monophosphate / Q000378:metabolism*; D007292:Inosine Nucleotides / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000187:drug effects*; D009708:Nucleotidases / Q000378:metabolism / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000201:enzymology* / Q000276:immunology
D001798:Blood Proteins; D007042:Hypoxanthines; D007292:Inosine Nucleotides; D007291:Inosine Monophosphate; D019271:Hypoxanthine; D007288:Inosine; D001377:Azaserine; D004247:DNA; D009708:Nucleotidases; D015720:5'-Nucleotidase; D000630:Aminopterin